UltraGreen.ai Maintains FY2026 Outlook Despite US Regulatory Nods; Shares Plunge 29%

Like
Comment
Favorite

UltraGreen.ai Maintains FY2026 Outlook Despite US Regulatory Nods; Shares Plunge 29%

MT Newswires13:54

UltraGreen.ai (SGX:ULG) said there has been no material change to its business or outlook following US regulatory approvals for Zydus Lifesciences and Provepharm, which were highlighted in a Business Times article, according to a filing with the Singapore Exchange.

The company said Thursday that FDA approval does not necessarily result in commercial launches, market adoption, or market penetration, while assumptions about competitors' manufacturing costs and future pricing were based on third-party analysts' views.

UltraGreen.ai maintained its FY2026 revenue guidance of $175 million to $185 million, with second-half revenue expected to exceed first-half revenue.

Shares of the healthcare services company plunged 29% in recent trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

Most Discussed

7x24

All

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2660180405?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-20 13:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2660180405","market":"sg","top_or_hot":-1,"title":"UltraGreen.ai Maintains FY2026 Outlook Despite US Regulatory Nods; Shares Plunge 29%","media":"MT Newswires","content":"<html><body><p> <a href=\"https://laohu8.com/S/ULG.SI\">UltraGreen.ai</a> (SGX:ULG) said there has been no material change to its business or outlook following US regulatory approvals for Zydus Lifesciences and Provepharm, which were highlighted in a Business Times article, according to a filing with the <a href=\"https://laohu8.com/S/S68.SI\">Singapore Exchange</a>.</p><p>The company said Thursday that FDA approval does not necessarily result in commercial launches, market adoption, or market penetration, while assumptions about competitors' manufacturing costs and future pricing were based on third-party analysts' views.</p><p>UltraGreen.ai maintained its FY2026 revenue guidance of $175 million to $185 million, with second-half revenue expected to exceed first-half revenue.</p><p>Shares of the healthcare services company plunged 29% in recent trade.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UltraGreen.ai Maintains FY2026 Outlook Despite US Regulatory Nods; Shares Plunge 29%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUltraGreen.ai Maintains FY2026 Outlook Despite US Regulatory Nods; Shares Plunge 29%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1060499803\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires </p>\n<p class=\"h-time\">2026-08-20 13:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/ULG.SI\">UltraGreen.ai</a> (SGX:ULG) said there has been no material change to its business or outlook following US regulatory approvals for Zydus Lifesciences and Provepharm, which were highlighted in a Business Times article, according to a filing with the <a href=\"https://laohu8.com/S/S68.SI\">Singapore Exchange</a>.</p><p>The company said Thursday that FDA approval does not necessarily result in commercial launches, market adoption, or market penetration, while assumptions about competitors' manufacturing costs and future pricing were based on third-party analysts' views.</p><p>UltraGreen.ai maintained its FY2026 revenue guidance of $175 million to $185 million, with second-half revenue expected to exceed first-half revenue.</p><p>Shares of the healthcare services company plunged 29% in recent trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0164939612.USD","symbol_name":"HSBC GIF ASIA EX JAPAN SMALLER CO. \"AC\" ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2660180405","we_media_id":"1060499803","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2660180405","pubTimestamp":1787205282,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"MT Newswires","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1060499803","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"UltraGreen.ai (SGX:ULG) said there has been no material change to its business or outlook following US regulatory approvals for Zydus Lifesciences and Provepharm, which were highlighted in a Business ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0164939612.USD":"HSBC GIF ASIA EX JAPAN SMALLER CO. \"AC\" ACC","LU0082770016.USD":"HSBC GIF ASIA EX JAPAN SMALLER CO. \"AD\" INC","BK6103":"医疗保健用品","ULG.SI":"优创康智有限公司","SG9999004311.SGD":"Nikko AM Shenton Emerging Enterprise Discovery Fund SGD","LU0082770016.SGD":"HSBC GIF ASIA EX JAPAN EQUITY SMALLER COMPANIES \"AD\" (SGD) INC","LU0620787316.HKD":"HSBC GIF ASIA EX JAPAN EQUITY SMALLER COMPANIES \"AD\" (HKD) INC","SG9999006266.SGD":"MANULIFE SINGAPORE EQUITY \"A\" (SGD) ACC","SG9999002406.SGD":"利安新加坡信托基金","SG9999002414.USD":"LIONGLOBAL SINGAPORE TRUST (USD) ACC"},"translate_title":"尽管美国监管机构批准，UltraGreen.ai 仍维持 2026 财年前景；股价暴跌 29%","themeId":"b010cf239ffd4765bcd3edd8f767f746","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ULG.SI":0.9},"content_text":"UltraGreen.ai (SGX:ULG) said there has been no material change to its business or outlook following US regulatory approvals for Zydus Lifesciences and Provepharm, which were highlighted in a Business Times article, according to a filing with the Singapore Exchange.The company said Thursday that FDA approval does not necessarily result in commercial launches, market adoption, or market penetration, while assumptions about competitors' manufacturing costs and future pricing were based on third-party analysts' views.UltraGreen.ai maintained its FY2026 revenue guidance of $175 million to $185 million, with second-half revenue expected to exceed first-half revenue.Shares of the healthcare services company plunged 29% in recent trade.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}